Sorafenib Completed Phase 2 Trials for Refractory Multiple Myeloma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00253578Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma